Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion (SAHARA)

• ClinicalTrials.gov Identifier: NCT04882358
• Recruitment Status: Recruiting
• First Posted: May 11, 2021
• Last Update Posted: June 1, 2021
• Sponsor: Sequana Medical N.V.
• Information provided by (Responsible Party): Sequana Medical N.V.

Study Description

Brief Summary:

Feasibility and safety study of the alfapump DSR system in the treatment of volume overloaded heart failure subjects receiving high doses of loop diuretics. Up to 24 subjects will be enrolled in up to 3 centres in Republic of Georgia, and randomized into 2 parallel treatment arms. Once implanted with the alfapump DSR system they will undergo DSR therapy in 2 phases: intensive treatment phase followed by maintenance treatment phase.

Condition or disease	Intervention/treatment	Phase
Heart Failure; Volume Overload	Device: ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM; Drug: SGLT2 inhibitor	Not Applicable

Detailed Description:

The feasibility trial will consist of a 24-subject randomized study in volume overloaded heart failure subjects receiving high dose of loop diuretics. Subjects providing consent for participating in the clinical trial will be screened for eligibility. Once eligibility is confirmed they will be implanted with the alfapump® and a standard peritoneal infusion port. After the implant, the subject will undergo a 40 mg IV furosemide (or 1 mg IV bumetanide) diuretic challenge with timed biospecimen collection. At the start of the study treatment period, the loop diuretics treatment will be stopped. Subjects will be randomized in an unblinded fashion into one of two groups:

• Group 1 (N= 12) - treatment with a standard dose of SGLT2-inhibitor, combined with DSR treatment (PRN use of loop diuretics)
• Group 2 (N= 12) - treatment with DSR treatment (PRN use of loop diuretics) Enrolled subjects in both groups will undergo at least two weeks of intensive alfapump® DSR treatment (Phase 1) followed by a maintenance and follow-up period of 16 weeks (Phase 2).

During Phase 1 (this can be an in-patient or an out-patient setting, depending on the local standard of care practices), DSR treatment will be performed in the hospital for each subject with the baseline treatment regimen being 1L 10% dextrose (DSR infusate) with a two-hour dwell time. During this phase 1 period, there will be 2 subsequent treatment intensities: Phase 1a) Active weight reduction and Phase 1b) Weight stabilization. The active weight reduction phase (phase 1a) will start with 3 consecutive daily DSR treatment visits in all subjects. Three consecutive daily visits are required to determine the subsequent DSR treatment frequency and dose. Prior to each planned DSR treatment, the subject is evaluated (weight, vital signs, and physical exam) and blood analysis is performed. Pending this evaluation, the next DSR treatment may be held, reduced (down-titrated) or escalated (up-titration) based on the proposed titration guidelines and at the discretion of the study physician. These titration guidelines differ depending on the (sub)treatment phase(s).

Before the end of the 2 intensive weeks (phase 1), many subjects may become already euvolemic and may transition from the active weight loss phase (1a) to the weight stabilization dosing phase (1b). The transition to phase 1b is based on either the resolution of signs and symptoms of volume overload and physician opinion of euvolemia or on the worsening of creatinine by 0.5mg/dL or 1.5x the subject's baseline serum creatinine. The dosing of DSR will employ identical steps as before, but the titration guidelines are adapted in order to stabilize the weight in phase 1b (rather than continue to lose weight).

After 2 weeks of DSR (end of phase 1), the subject's condition will be evaluated via a diuretic challenge before entering the Phase 2 maintenance phase of the study. Transition to Phase 2 is recommended if all of the following criteria are met

• Clinical euvolemia is achieved (clinical assessment by investigator);
• Diuretic response during diuretic challenge is >200mmol Na or 50% increase or 50 mmol Na increase from baseline
• Stable DSR dosing was achieved If these criteria are not met, it is recommended that a 2nd 2-week Phase 1 period is utilized. To ensure ease of enrolment and compliance with the protocol, this is a recommendation rather than a protocol mandate. Up to three 2-week Phase 1 periods (6 weeks total) are allowable per protocol.

During phase 2 all subjects will receive DSR using 1L of D10 in a monthly maintenance treatment session. In case a subject exhibits weight gain greater than 2.5kg or 50% than the weight at the end of Phase 1, loop diuretics (bumetanide, chosen for its short half-life, thus minimizing the time each day the kidney is exposed to loop diuretics) may be started using a proposed dosing schedule. The maintenance phase will last 4 months after subject has started this phase 2. Total maximum study duration (screening until end of phase 2) for each subject will be 6,5 months. During the maintenance period, subjects will be followed weekly (hospital visit or telephone call). Subjects who relapse to congestion state will be undergoing additional active DSR treatment in dose and frequency as deemed required per their clinical needs by treating physician, until decongested state is reached again. In case a subject present with repeat symptoms of volume overload or decongestion, which would necessitate a repeat of phase I treatment, this will not prolong initial 4 months duration of phase 2. The recurrent decongestion will need to be reported as (S)AE and will be followed up until resolution. At the end of the phase 2 phase, each subject undergoes a diuretic challenge to evaluate diuretic response.

At the end of the phase 2 phase, subjects may elect to keep the alfapump® DSR system implanted, in agreement with the investigator. After consenting, subjects can participate in an extended follow-up with or without DSR treatments until the end of the alfapump® DSR system lifecycle (expected maximum 2 years). In other indications (not DSR) where the alfapump® is implanted, an average pump lifecycle of 10 months is observed. During the extended follow up period, no replacement of alfapump®, peritoneal access port or alfapump catheters will be performed.

The objective of the extended follow-up is to collect more long-term safety data. For subjects for whom DSR therapy appears to be offering a benefit, the investigator can elect to offer continued monthly DSR treatment at his/her discretion, in close collaboration with scientific study management team. Subjects participating in this extended follow-up will be asked to perform an additional diuretic challenge every 3 months during the extended FU to evaluate their diuretic response.

Subjects not participating in the proposed study extension as well as subjects who elected to have the alfapump® explanted at the end of the phase 2, will be proposed to participate in a minimal extended follow-up to allow investigator to contact them monthly to gather information only on loop diuretic restart and dose after the end of the study (with a maximum of 1 year after the end of phase 2 treatment period).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 24 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Multicenter, randomized, open label, feasibility and safety study
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Alfapump® DSR Feasibility Study in Subjects With Persistent Congestion Due to Heart Failure, Resistant to Loop Diuretic Treatment
• Actual Study Start Date: May 27, 2021
• Estimated Primary Completion Date: November 30, 2022
• Estimated Study Completion Date: December 31, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: GROUP 1 DIRECT SODIUM REMOVAL + SGLT-2 INHIBITOR; SUBJECTS TREATED WITH DSR + STANDARD DOSE OF APPROVED SGLT-2 INHIBITOR	Device: ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM; Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump; Drug: SGLT2 inhibitor; treatment with a standard dose of SGLT-2 inhibitor; Other Name: dapagliflozin
Experimental: GROUP 2 DIRECT SODIUM REMOVAL; SUBJECTS TREATED WITH DSR	Device: ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM; Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump

Outcome Measures

Primary Outcome Measures :

1. Safety - Treatment related SAE [ Time Frame: up to day 156 ]
   Rate of treatment related serious adverse events
2. Safety - Device related SAE [ Time Frame: up to day 156 ]
   Rate of Device related serious adverse events
3. Safety - Procedure related SAE [ Time Frame: up to day 156 ]
   Rate of Procedure related serious adverse events

Secondary Outcome Measures :

1. Safety - Treatment related [ Time Frame: day 14 ]
   Rate of treatment related serious adverse events
2. Safety - Treatment related [ Time Frame: day 128 ]
   Rate of treatment related serious adverse events
3. Safety - Treatment related [ Time Frame: up to day 156 ]
   Rate of treatment related serious adverse events
4. Safety - Device related [ Time Frame: day 14 ]
   Rate of Device related serious adverse events
5. Safety - Device related [ Time Frame: day 128 ]
   Rate of Device related serious adverse events
6. Safety - Device related [ Time Frame: up to day 156 ]
   Rate of Device related serious adverse events
7. Safety - Procedure related [ Time Frame: day 14 ]
   Rate of Procedure related serious adverse events
8. Safety - Procedure related [ Time Frame: day 128 ]
   Rate of Procedure related serious adverse events
9. Safety - Procedure related [ Time Frame: up to day 156 ]
   Rate of Procedure related serious adverse events
10. Safety - Device Deficiencies [ Time Frame: day 14 ]
    Rate of device deficiencies
11. Safety - Device Deficiencies [ Time Frame: day 128 ]
    Rate of device deficiencies
12. Safety - Device Deficiencies [ Time Frame: up to day 156 ]
    Rate of device deficiencies
13. Weight loss ≥ 5kgs [ Time Frame: day 14 ]
    % of subjects reaching weight loss of ≥ 5kgs
14. Weight change [ Time Frame: day 14 ]
    Change in weight from baseline
15. Weight change [ Time Frame: day 128 ]
    Change in weight from baseline
16. Weight change [ Time Frame: up to day 156 ]
    Change in weight from baseline

Other Outcome Measures:

1. Euvolemic state [ Time Frame: day 14 ]
   Time to reach euvolemic state
2. Euvolemic state [ Time Frame: day 128 ]
   Time euvolemic state is maintained in maintenance period
3. Restart PRN Loop diuretic treatment [ Time Frame: up to day 156 ]
   Time to restart of PRN loop diuretic treatment
4. Restart Loop diuretic treatment [ Time Frame: up to day 156 ]
   Time to restart of systematic loop diuretic treatment after start of DSR treatment
5. Time Loop diuretic treatment reaching dose [ Time Frame: up to day 156 ]
   Time to reach loop diuretic treatment dose ≥ loop diuretic dose prior to DSR treatment start
6. Time increase Loop diuretic treatment [ Time Frame: up to day 156 ]
   Time to loop diuretic dose increase once on therapy
7. Amount Loop diuretic treatment [ Time Frame: up to day 156 ]
   Total mg of loop diuretic administered
8. Change Renal function - urea [ Time Frame: up to day 156 ]
   Change in renal function -urea from baseline through treatment
9. Change Renal function - creatinin [ Time Frame: up to day 156 ]
   Change in renal function -creatinin from baseline through treatment
10. Change Hemoconcentration markers - serum hematocrit [ Time Frame: up to day 156 ]
    Change in hemoconcentration markers (serum hematocrit) from baseline through treatment
11. Change Hemoconcentration markers - serum hemoglobin [ Time Frame: up to day 156 ]
    Change in hemoconcentration markers (serum hemoglobin) from baseline through treatment
12. Hemoconcentration markers - serum albumin [ Time Frame: up to day 156 ]
    Change in hemoconcentration markers (serum albumin) from baseline through treatment
13. Change Hemoconcentration markers - total serum protein [ Time Frame: up to day 156 ]
    Change in hemoconcentration markers (total serum protein) from baseline through treatment
14. Change N-Terminal Prohormone of Brain Natriuretic Peptide (nt-ProBNP) [ Time Frame: up to day 156 ]
    Change in nt-proBNP from basline through treatment
15. Change Hemoglobin A1c [ Time Frame: day 128 ]
    Change in hemoglobin A1c
16. DSR doses [ Time Frame: up to day 156 ]
    Number of DSR doses per week
17. Amount of 10% Dextrose infusate [ Time Frame: up to day 156 ]
    Amount of 10% Dextrose infusate given
18. DSR dose adjustments [ Time Frame: day 14 ]
    Number of DSR dose adjustments
19. DSR dose adjustments [ Time Frame: day 128 ]
    Number of DSR dose adjustments
20. Sodium [ Time Frame: up to day 156 ]
    Net sodium loss with each DSR treatment (8 hours of DSR exposure)
21. Urine volume [ Time Frame: up to day 156 ]
    Net fluid loss with each DSR treatment (8 hours of DSR exposure)
22. Change 6-hour diuretic challenge response [ Time Frame: day 14 ]
    Change in response to 6 hour diuretic challenge from baseline
23. Change 6-hour diuretic challenge response [ Time Frame: day 128 ]
    Change in response to 6 hour diuretic challenge from baseline
24. Change 6-hour diuretic challenge response [ Time Frame: up to day 156 ]
    Change in response to 6 hour diuretic challenge from baseline
25. Change Plasma electrolytes - sodium [ Time Frame: up to day 156 ]
    Change in plasma electrolytes - Sodium from baseline
26. Change Plasma electrolytes - potassium [ Time Frame: up to day 156 ]
    Change in plasma electrolytes - potassium from baseline
27. Change Plasma electrolytes - magnesium [ Time Frame: up to day 156 ]
    Change in plasma electrolytes - magnesium from baseline
28. Change Plasma electrolytes - calcium [ Time Frame: up to day 156 ]
    Change in plasma electrolytes - calcium from baseline
29. Change Plasma electrolytes - phosphor [ Time Frame: up to day 156 ]
    Change in plasma electrolytes - phosphor from baseline
30. DSR dwell time [ Time Frame: up to day 156 ]
    Dwell time per DSR treatment
31. Change Bio-impedance vector analysis [ Time Frame: up to day 156 ]
    Change in Bio-impedance vector analysis
32. Ultrafiltration [ Time Frame: up to day 156 ]
    Total ultrafiltration
33. Volume [ Time Frame: up to day 156 ]
    Total volume removed
34. Glucose [ Time Frame: up to day 156 ]
    Total glucose resorption during DSR treatment

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Subject is ≥18 years of age
2. Subject has creatinine based eGFR (MDRD or CKD-EPI formula) >30ml/min/1.73m²

3. Subject is diagnosed with heart failure including the follow-ing:

   1. nt-proBNP > 2000 pg/ml and oral diuretic dose >80mg furosemide (or >20mg torsemide or >1mg bume-tanide)
   2. at least 1 hospitalization due to HF-related volume overload within the year prior to enrolment in the study
   3. at least 2 clinical signs and symptoms of volume over-load

4. Subject has extravascular volume overload as evidenced by:

   1. Peripheral edema > trace
   2. Known fluid weight gain, or physician estimate of ≥5kg of fluid overload;
5. Subject has systolic blood pressure ≥ 100 mmHg
6. Subject is able to tolerate surgical implantation of the alfapump using local standard of care anesthesia practices

Exclusion Criteria:

1. Subject has proteinuria > 1g/l as confirmed by dipstick (≥ +++)
2. Subject presents an excessive subcutaneous fatty tissue layer at the intended location of alfapump implant, or with other characteristics which could interfere with implantation procedure or transcutaneous charging of the alfapump.
3. Subject has anemia with hemoglobin < 8g/dL
4. Subject has serum sodium < 135 mEq/L
5. Subject has clinical signs of low output heart failure
6. Subject has severe cardiac cachexia
7. Subject has history of severe hyperkalemia or screening plasma potassium > 4.5 mEq/L (K can be 4.5-5 meq/L if on 40meq or greater daily potassium supplementation and this can be stopped for the study).
8. Subject has significant non-cardiac disease or comorbidities expected to reduce life expectancy to less than 1 year.
9. Subject has cirrhosis or history of clinically significant ascites (i.e., prior large volume paracentesis) or large volume ascites on imaging or exam
10. Subject has hemodynamically significant stenotic valvular disease
11. Subject is receiving anti-coagulative or anti-platelet treatment which cannot be withheld for 5 days (replaced by bridging therapy low molecular weight heparin or unfractionated heparin) prior to and 2-3 days after alfapump DSR system implantation;
12. Subject has suffered myocardial infarction (MI), cerebro-vascular accident (CVA) or transient ischemic attack (TIA) within 90 days prior to enrolment in the study
13. Subject has history of peritonitis or history of abdominal surgery with increased risk of major abdominal adhesion as assessed by the investigator
14. Subject has any active infection or history of recurrent urinary tract infection or history of current urosepsis
15. Subject has history of renal transplant
16. Subject has history of significant bladder dysfunction expected to interfere with ability of subject to tolerate DSR pumping into bladder
17. Subject has uncontrolled diabetes with frequent hyperglycemia or Type 1 diabetes
18. Subject has urinary incontinence
19. Subject has history of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months
20. Subject is pregnant or is breastfeeding or intends to become pregnant during the study
21. Subject has severe peripheral artery disease
22. Subject has hypersensitivity to SGLT2 inhibitors
23. Subject is currently participating in another clinical trial
24. Subject is unable or unwilling to comply with all required study follow-up procedures

Contacts and Locations

Contacts

Contact: Danny Detiège, RN; +32 9 292 8065; danny.detiege@sequanamedical.com

Contact: Oliver Goedje, MD; +32 9 292 8065; oliver.goedje@sequanamedical.com

Locations

Georgia

Israeli-Georgian Medical Research Clinic Helsicore; Not yet recruiting

Tbilisi, Georgia, 0112

Contact: Mamuka Kobalava, MD

Contact: Tamila Diasamidze, RN

Principal Investigator: Mamuka Kobalava, MD

Tbilisi Heart & Vascular Clinic; Recruiting

Tbilisi, Georgia, 0159

Contact: Tamaz SHABURISHVILI, MD +995599502244 tamaz_shaburishvili@yahoo.com

Contact: TAMAR BIGVAVA, MD +995598111355 tamri.bigvava@gmail.com

Principal Investigator: Tamaz SHABURISHVILI, MD

Sponsors and Collaborators

Sequana Medical N.V.

Investigators

• Principal Investigator: TAMAZ SHABURISHVILI, MD; TBILISI HEART & VASCULAR CLINIC

More Information

• Responsible Party: Sequana Medical N.V.
• ClinicalTrials.gov Identifier: NCT04882358
• Other Study ID Numbers: 2019-CHF-006
• First Posted: May 11, 2021
• Last Update Posted: June 1, 2021
• Last Verified: May 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: No IPD data will be shared with other researchers

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sequana Medical N.V.:

sodium; alfapump; direct sodium removal; diuretic resistance

Additional relevant MeSH terms:

Heart Failure; Heart Diseases; Cardiovascular Diseases; Dapagliflozin; Sodium-Glucose Transporter 2 Inhibitors; Molecular Mechanisms of Pharmacological Action; Hypoglycemic Agents; Physiological Effects of Drugs